Medical Cannabis for Advanced Pancreatic and Colorectal Cancer
This study is looking at whether medical cannabis can help patients with advanced pancreatic or colorectal cancer manage difficult symptoms. Many patients with these cancers experience a lot of symptoms that can affect their quality of life. Current treatments often don't work well enough, and there's a need for better options. This study will provide medical cannabis to some participants right away, while others will receive it later. The main goal is to see if it's practical to conduct a larger study on medical cannabis for these conditions, by checking how many people join, how well they follow the study plan, and if they stick with their assigned group. This study is currently unclear on its recruitment status and plans to enroll 64 participants.
- Study design
- This is an interventional study where participants will be randomly assigned to either receive medical cannabis early or after an 8-week delay. It aims to enroll 64 participants.
- What's involved
- If you are in the early cannabis group, you will receive medical cannabis for 8 weeks and then be observed for another 8 weeks. If you are in the delayed group, you will not use cannabis for the first 8 weeks, then use it from weeks 8 to 16. You will complete weekly and every-4-week surveys.
- Compensation
- Medical cannabis will be provided at no charge for the first 8 weeks for the early group. If the early group chooses to continue cannabis for another 8 weeks, they will be responsible for the cost.
- Follow-up
- Participants in the early cannabis group will be observed for 8 weeks after cannabis initiation. Participants in the delayed cannabis group will be observed for 8 weeks after randomization.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Medical Cannabis in Patients With Advanced Pancreatic and Colorectal Cancer
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Assess feasibility for conducting a larger randomized trial by determining rate of recruitment, compliance with randomization group, and protocol adherence to this clinical trial.Early Cannabis - 8 weeks from cannabis initiation; Delayed Cannabis - 8 weeks from randomization
Achieve successful completion of feasibility trial by demonstrating the following: a) 64 patients enrolled (enrollment goal in each cohort is to enroll 32 patients within an 18 month period), b) at least 60% of eligible patients who are offered participation enroll in the trial, c) at least 20% of patient screened for eligibility enroll in the trial, d) at least 60% of patients comply with randomization group through week 8, and e) patients in both early and delayed group complete at least 50% of weekly PROs through week 8.